The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

The FDA intends to place a black box label—its most serious warning—on COVID-19 vaccines, according to reporting by CNN. It ...

The FDA has cleared the use of GSK’s Blujepa for the treatment of uncomplicated urogenital gonorrhea, unlocking the first new ...

The 2024–2025 formulations of COVID-19 vaccines had an effectiveness rate of 76% at preventing emergency or urgent care ...

Generalized myasthenia gravis is Uplizna’s second new indication this year, after the FDA cleared the anti-CD19 antibody for ...

With five CDER leaders in one year and regulatory proposals coming “by fiat,” the FDA is only making it more difficult to ...

Also on Thursday, Zealand held its Capital Markets Day in London, outlining the strategy for its weight management franchise ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

While new late-stage data point to some liver toxicity signals, analysts at BMO Capital Markets said Tukysa’s efficacy ...

The FDA is becoming deeply compromised and increasingly at risk of being permanently transformed in ways contrary to its ...

Roche’s data on Wednesday come from the Phase III lidERA Breast Cancer study, which assessed the adjuvant use of giredestrant ...

Pfizer is in the midst of an aggressive, multi-year cost-cutting effort, which so far has left nearly 2,000 people jobless.